Treatment COVID-19: France banned the drug, who took trump

In French hospitals experienced hydroxychloroquine as a medication COVID-19

The French government overturned the provision that allowed the use of anti-malarial drug hydroxychloroquine for the treatment of patients in hospitals with novel coronavirus infection. This was reported by the Journal-officiel.

“Regulation 19 of the decree of 11 may 2020 cancelled”, – stated in the document. In particular, the provision stated that “… the hydroxychloroquine can be administered in health institutions under the responsibility of the doctor to patients with COVID-19”.

Previously, the French medicines Agency announced its intention to suspend as a precaution the test of hydroxychloroquine as a medication COVID-19. However, the Agency noted that “patients treated with hydroxychloroquine as part of these tests will be able to continue the course until the end of the Protocol.”

According to authorities, only in France at the moment are 16 of these clinical trials.

Note, the High Council for health of France had recommended to abandon the use of hydroxychloroquine in the treatment of COVID-19 outside of clinical trials. This recommendation was announced after the Minister of health of France, Olivier Veran asked to revise the rules of use of this drug in connection with the publication in the medical journal The Lancet study, which refers to ineffective and even harmful in some cases, the use of chloroquine in the treatment of patients with coronavirus.

May 25 Director General of the world health organization (who), Tedros Aden Gebreyesus said that the organization had temporarily suspended trials of hydroxychloroquine and chloroquine in the treatment of COVID-19.

We will remind, not so long ago the US President Donald trump said that many Americans, including himself, are taking hydroxychloroquine to protect themselves from pandemic COVID-19.

According to the latest University of Hopkins in the world 5 079 609 confirmed cases of infection with coronavirus, died 350 862 people.